Articles

PharmiWeb.jobs a new jobs board
PharmiWeb are very excited to be launch the new version of our world class Job Board PharmiWeb.jobs, as well as the latest Pharma News Portal PharmiWeb.com.To search for the best selections of Pharma Jobs in Europe visit pharmiweb.jobsTo find the widest range of pharma news, events and articles, search on this site!

The most technically advanced life sciences businesses know that in today’s world, digital innovation and platform hyper-connectivity are no longer a luxury. Technological innovations in clinical trials are increasingly necessary for enabling drug development. Life Sciences as an industry has an enormous opportunity to improve efficiency and cut costs, whilst extending the scope of its research and improving patient and clinical experiences.
The most technically advanced life sciences businesses know that in today’s world, digital innovation and platform hyper-connectivity are no longer a luxury. Technological innovations in clinical trials are increasingly necessary for enabling drug development. Life Sciences as an industry has an enormous opportunity to improve efficiency and cut costs,…

In its first ever pan European research on the life sciences industry, Kelly asked almost 1,400 of its workers their opinions on everything from work life design, to AI, through to what matters most to them. With respondents from Germany, France, the UK, Ireland, the Netherlands, Switzerland and Italy it was surprising to find so many commonalities between each of the countries.
The life sciences are all about diversity and movement, which is why Pharma and Medical Devices companies may need more than just a good reputation after Brexit. As the United Kingdom drifts towards an exit from the European Union, the Pharma and Medical Devices sectors are preparing for all eventualities. However, the employment landscape is already highly competitive and it is shifting. With a widespread skills s…

Dr Rachael Benstead, senior aquatic ecotoxicologist at translational science and research organisation, Fera Science Ltd, looks at bioconcentration and biomagnification and what is being done to protect our planet.
The environment and the organisms living in it are continuously exposed to a wide range of chemicals. From chlorine-based solutions that remove bacteria from water to pesticides that treat and protect crops. However, through bioconcentration and the theory of biomagnification, some of these chemicals can become dangerous to our world. Here, Dr Rachael Benstead, senior aquatic ecotoxicologist at translational science and research organisation, Fera Science Ltd, looks at bioconcentration and biomagnification and what is being done to protect our planet. With every chemical pro…

Rachael Benstead, senior aquatic ecotoxicologist at Translational science and research organisation, Fera Science Ltd, helps plot a roadmap to a future in which we can take advantage of the benefits of nanotechnology in water and mitigate against the drawbacks.
It is entirely conceivable that the engineered nanoparticles that seem like today's water treatment panacea, could be tomorrow's ecological dynamite. The potential for the use of nanoparticles in water treatment such as water filtration is too compelling to ignore, despite the potential risks. Here, Rachael Benstead, senior aquatic ecotoxicologist at Translational science and research organisation, Fera Science Ltd, helps plot a roadmap to a future in which we can take advantage of the benefits of nanotechnology in water and mitiga…

Paul Mannion, project engineer at engineering solutions provider Boulting, explains the considerations that should be made when designing for builds in hazardous environments.
When Mount Vesuvius erupted in AD79, the citizens of Pompeii were not prepared for the devastation that followed. Having lain dormant for the last 71 years, the Italian authorities continue to prepare for the next eruption from one of the most dangerous active volcanos in the world. Here, Paul Mannion, project engineer at engineering solutions provider Boulting, explains the considerations that should be made when designing for builds in hazardous environments.   The Dangerous Substances and Explosive Atmosphere Regulations 2002 (DSEAR), defines a hazardous area as “any place in which an explosive atmo…

Almost half of over 65s in England take at least five different drugs each day, according to a 2017 study conducted at the University of Cambridge. Here, Oliver Pittock, from medical packaging experts, Valley Northern, explores what can be done to help the ageing population keep safe around prescribed medications and avoid mishaps.
Almost half of over 65s in England take at least five different drugs each day, according to a 2017 study conducted at the University of Cambridge. The increasing rates of polypharmacy, taking multiple medications simultaneously, means that prescribing for the elderly is becoming an increasingly important aspect of clinical patient care. Here, Oliver Pittock, managing director at medical packaging experts, Valley Northern, explores what can be done to help th…

Learning the microbead lesson
A UK-wide prohibition on the use of plastic microbeads came into effect in 2018, but what fundamental lessons can we learn from this high profile case? Dr Rachael Benstead, senior aquatic ecotoxicologist at translational science and research organisation, Fera Science Ltd. explains all.   Figures from The Department for the Environment, Food and Rural Affairs (DEFRA) suggest that an estimated 680 tonnes of microbeads are used in cosmetic products every year. These tiny pieces of plastic, used for exfoliation in rinse-off products such as toothpastes, face scrubs and shower gels, inevitably end up contaminating the environment.   With particle sizes varying from 10 micrometers up to 1 millimetre, microbeads are the same size as much of the…

Preclinical IPOs: Is the window starting to close?
A record-breaking year is on the cards, as biotechnology companies continue the trend of pre-clinical initial public offerings (IPOs). As of July, six young firms had raised almost $800million through their IPOs, despite none having permission from regulators to start clinical trials in humans.[1] These companies are now generating significant returns. For example, the most recent preclinical IPO by Gritstone Oncology Inc was initially valued at $100 million, and as of 12 December 2018 has a market value of $731 million.1 Pre-clinical valuations Traditionally, there are two good times for biotech companies to go public: right after proof or concept in humans or upon the publication of promising, pivotal data.  But these pre-cl…

~ Unpacking the potential of smart packaging ~ One of the biggest challenges for manufacturers of consumable goods is how to extend product shelf life while ensuring safety. Over the past hundred years, the food and beverage industry has invested billions of pounds in researching suitable packaging, but what can the pharmaceutical industry learn from this?
Here, Dale Pittock, sales director of pharmacy consumables provider Valley Northern, explores the latest developments in the smart packaging market. Imagine if a packet of antibiotics could tell a patient whether it had been opened and which pill had been taken and at what time. Then, imagine if things could be taken a step further and the medication could alert patients when it was time to take the next one, then feed this informat…

~ Pharmacy and healthcare supplier releases advisory whitepaper ~
Leading pharmacy and healthcare consumables supplier, Valley Northern, has released its latest whitepaper, exploring the increasing issue of patient non-adherence. The whitepaper, which can be downloaded directly from the Valley Northern website, looks at why non-adherence is an issue and how those across the healthcare industry can help to tackle it. Download the whitepaper here: Valley Northern Downloads.Across the United Kingdom, one billion items are prescribed and dispensed by pharmacists every year. However, one in five patients surveyed as part of a recent industry report admitted to not taking their medication as prescribed. The issue of patient non-adherence is a big issue, particularly when patients try to take thei…

How technology at an operational level is the driving force behind innovative pharmaceutical businesses

The global pharmaceutical industry is often held up as an example of a sector that exists on the cutting edge of what is possible. But that doesn’t mean that it can avoid its own tech disruption.

Digitalisation - the process of moving to digital business processes and away from legacy and paper-based ones -  is changing the pharmaceutical industry just as it is changing many others. One seemingly simple, yet business-critical change will be in how companies collect, share and analyse data, with the result that digitalisation will have a radical effect on how products and processes are audited.

When a consumer buys aspirin, paracetamol or any of the thousands of over-the-counter medic…

Neo4j’s Emil Eifrem takes a look at how life science researchers can use graph databases to get granular insight from big data and make real advances in research
Neo4j’s Emil Eifrem takes a look at how life science researchers can use graph databases to get granular insight from big data and make real advances in researchBig data, defined as large complex data sets, has the potential to throw light onto every link in the life sciences value chain, which is why data mining has become so important to researchers – but having the right technology is key to its success.Traditional database tools, namely SQL and relational database technology, find the volume as well as the unstructured nature of these complex datasets extremely difficult to work with. Why? Because they model the world as a set…

How Finance 4.0 can deliver cutting-edge technology to the pharmaceutical industry
The pharmaceutical industry is increasingly making use of modern digitalised technology to automate specific processes in drug development, testing and manufacturing, one UK based company predicts they will be able to commercialise printed tablets (using 3D printing) within the next 5 to 10 years.[1] New techniques such as personalised medicine, where the care and treatment of patients moves away from a ‘one size fits all’ approach and instead uses diagnostics, genomics and data analytics to identify the underlying cause of disease, have encouraged a wave of activity in the biotech sector, with several companies now offering a range of complex gene editing services.[2]Similarly, Artificial Intelligence (AI) i…

Managing translations for submissions in regulatory affairs – what is best practice?
Managing translations for submissions in regulatory affairs – what is best practice? Few heads of regulatory affairs would dispute the complexity of compliance and regulation in the life sciences industry. Changing regulations puts greater pressure on regulatory professionals and makes the job of translating content for submissions ever more difficult, while the pressure to decrease time-to-market for life-saving new drug therapies grows all the time. Regulations change so frequently in countries all the time, that there is an almost constant re-evaluation as to what is needed to be included in dossiers and what parts of the dossier require translation. Given such challenges, whether handling translations…

Maintaining the highest recruitment standards puts pharma companies at ease
With the pharmaceutical industry experiencing unprecedented talent shortages, the importance of finding a trusted partner to supply talent that can deliver to the highest professional standard has never been greater, which is why SEC has announced their delight at once again obtaining both bronze and silver Workforce Quality Accreditation from IAOCR.The accreditation – awarded to organisations that demonstrate a commitment to professionalism and competence in their own workforce – included a full analysis of SEC’s working practices and following the re-accreditation, Global Head of Workforce Strategy and Innovation Angela O’Connell, said “From the initiation of the Workforce Quality Accreditation, SEC Recruitment ha…

More focus on SRG Clinical – this time in Europe!
More focus on SRG Clinical – this time in Europe!Since 1990, SRG’s Clinical division has been committed to providing outstanding temporary, contract and permanent resourcing services to its clients and career opportunities in all areas of clinical research and drug development across the UK and Europe. Following the exciting progress of SRG’s Clinical team over the last year, we have now taken the next step in pursuing our growth plans by appointing Julian Stec to fly the SRG flag in Poland and beyond. This appointment will expand our Clinical Business Development function and solidify our presence in Europe.Based in Warsaw and focusing on expanding our presence with existing and new clients, Julian comes with the great advantage of experti…

Clinical Research – Quo Vadis?
Clinical Research – Quo Vadis?In recent times we began observing a significant acceleration of technology development which aims at improving the quality and speed of clinical trials as well as lowering the costs of it.It would seem that moving from simple paper digitalization to IoE (Internet of Everything) and Big Data will reduce the demand for qualified on-site CRA workforce. But will it? And would it completely wipe out the needs? There are ones who prophesies this is inevitable, but personally, I doubt that. Why, you may ask? GCP regulation is very clear about it - ICH GCP 5.18.1 (a) states: “The purpose of clinical trial monitoring is to verify that the rights and well-being of human subjects are protected.” Although today's CRA skillset is far mor…

What’s a strategic partnership between friends?
A few weeks ago, my colleague Marianna in London shared her thoughts on strategic partnerships and since this service offering is one of the areas I focus on, I wanted to add a few thoughts of my own. What do you first think of when hearing of a strategic partnership? A picture of a bunch of CXOs shaking hands and smiling? Bosses sending emails to the staff guiding them through the principles of a new corporate programme or introducing the company’s latest leaders? Another weekly call with half a dozen consultants? Pretty often that’s exactly what we get. What do you first think of when getting into a new close friendship? It might be something like: It’s amazing how much we have in common; I have never been listened to that…

Don’t work hard, work smart!
In recent years there has been loads of talk about strategic partnerships. And whilst some organisations feel hesitant to partner with clients too closely for fear of putting all their eggs into the same basket, it can actually be quite beneficial if done smartly. I would like to go even further – strategic partnerships can become an independent service offering to our clients! With the evolution of talent acquisition over the last 10-15 years, gone are the days when we worked directly with the hiring manager who could make all their hiring decisions alone, sign T&Cs and take our candidate through the entire recruitment process in 2 days…. We now all work through centralised, metrics-monitored, cost conscious, report producing MSPs, RPOs and VMS soluti…